This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and that can drive the interest in biotechs ever higher.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include CenturyLink, Gold Fields, Papa John's, Priceline, SolarCity, Tesla Motors and Unisys.
The overwhelming cascade of insider buyers should come as no surprise, given the huge drops in the market over the past week and a half.
The top analyst upgrades, downgrades and other research calls from Wednesday include Blackstone, Ciena, Merck, Tempur Sealy and Universal Display.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All American, Salesforce,com, Tesla and Yelp.
Source: ThinkstockStocks seem to be migrating from a tired bull market phase into a phase of volatility. It is also a phase where broad-based upside might not be an automatic assumption going...
The good news from JCPenney (JCP) was that it finished the year with $3.4 billion in cash.The bad news is that the company is slowly disappearing. It expects same-store sales in the current quarter...
Anyone looking at Wal-Mart’s (WMT) results would have have been terribly misled about the state of American retail.JC Penney (JCP) showed what retail really looks like in a recession. JPC reported...
Source: courtesy J.C. Penney Co. Inc.CNBC reported a rumor that a block of J.C. Penney Co. Inc. (NYSE: JPC) stock was for sale, with the transaction represented by Deutsche Bank. The Wall Street...
Eddie Lampert, the chairman and controlling shareholder of Sears Holdings (NASDAQ: SHLD), has been accused of being a fool and poor operator more than once. Sears results proved once more than the...
Source: courtesy J.C. Penney Co. Inc.If The Wall Street Journal is accurate, J.C. Penney (NYSE: JPC) has hired turnaround firm AlixPartners to help it “identify cost savings and manage cash...
Source: courtesy J.C. Penney Co. Inc.J.C. Penney Co. Inc. (NYSE: JPC) is really up against it. Several media outlets report that it will try to raise $1 billion, as new CEO Myron Ullman III labors to...
Piper Sandler has initiated coverage of Galera Therapeutics with an Overweight recommendation.